Tag #Glp-1 Ras

Showing 1 to 4 of 4 results

theguardian.com

🌐 85% Global Worthiness

Jun 5, 22:15

GLP-1 RA Drugs May Double Macular Degeneration Risk in Diabetic Patients

A Canadian study of over 1 million Ontario residents with diabetes revealed that GLP-1 RA drugs, such as semaglutide and lixisenatide, may at least double the risk of developing neovascular age-related macular degeneration after six months of use, particularly in older patients or those with a histo...

GLP-1 RA Drugs May Double Macular Degeneration Risk in Diabetic Patients

A Canadian study of over 1 million Ontario residents with diabetes revealed that GLP-1 RA drugs, such as semaglutide and lixisenatide, may at least double the risk of developing neovascular age-related macular degeneration after six months of use, particularly in older patients or those with a histo...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What factors increase the risk of developing neovascular age-related macular degeneration in patients using GLP-1 RA drugs?

The study, published in Jama Ophthalmology, analyzed data from over 1 million Ontario residents with diabetes. Researchers compared 46,334 patients using GLP-1 RAs to a control group. The findings suggest a significant association between GLP-1 RA use and increased macular degeneration risk, particularly in older patients or those with a history of stroke.

theguardian.com

🌐 85% Global Worthiness

Feb 17, 19:09

Wegovy Approved for Heart Disease Treatment in Australia

Australia's TGA approved Wegovy (semaglutide) in December 2024 for treating cardiovascular disease in overweight and obese adults, reducing heart attack/stroke risk by 20% in a 17,604-person Select trial, but PBS listing remains undecided due to cost.

Wegovy Approved for Heart Disease Treatment in Australia

Australia's TGA approved Wegovy (semaglutide) in December 2024 for treating cardiovascular disease in overweight and obese adults, reducing heart attack/stroke risk by 20% in a 17,604-person Select trial, but PBS listing remains undecided due to cost.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How did the Select trial contribute to Wegovy's expanded indication, and what were its key findings?

The approval is based on the Select trial's results, showing Wegovy's efficacy in reducing cardiovascular events even in patients without diabetes. This expands the therapeutic potential of GLP-1 RAs beyond their initial diabetes indication, highlighting their impact on inflammation, blood lipids, and blood pressure.

foxnews.com

🌐 85% Global Worthiness

May 14, 13:15

GLP-1 Receptor Agonists Show Comparable Effectiveness to Bariatric Surgery in Reducing Obesity-Related Cancer Risk

An Israeli study of 6,356 obese individuals with diabetes found that GLP-1 receptor agonists (GLP-1 RAs) and bariatric metabolic surgery showed similar low rates of obesity-related cancers, with GLP-1 RAs showing a 41% relative risk reduction compared to surgery; further research is needed to confir...

GLP-1 Receptor Agonists Show Comparable Effectiveness to Bariatric Surgery in Reducing Obesity-Related Cancer Risk

An Israeli study of 6,356 obese individuals with diabetes found that GLP-1 receptor agonists (GLP-1 RAs) and bariatric metabolic surgery showed similar low rates of obesity-related cancers, with GLP-1 RAs showing a 41% relative risk reduction compared to surgery; further research is needed to confir...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do the anti-inflammatory and metabolic effects of GLP-1 RAs potentially contribute to their observed impact on obesity-related cancer risk?

The study indicates GLP-1 RAs may reduce ORC risk through mechanisms beyond weight loss, potentially by reducing inflammation and improving metabolic health. Experts suggest these medications' anti-inflammatory properties and metabolic regulation contribute to this effect, alongside possible direct anti-tumor effects. This highlights a potential additional benefit of GLP-1 RAs beyond weight management.

forbes.com

🌐 85% Global Worthiness

Jan 30, 19:11

Ozempic and Surgery: Increased Aspiration Risk

The U.K.'s MHRA warns that weight-loss drugs like Ozempic increase the risk of aspiration (stomach contents entering the lungs) during surgery due to slow gastric emptying, reporting a small number of cases, one resulting in aspiration pneumonia; patients should inform their healthcare providers.

Ozempic and Surgery: Increased Aspiration Risk

The U.K.'s MHRA warns that weight-loss drugs like Ozempic increase the risk of aspiration (stomach contents entering the lungs) during surgery due to slow gastric emptying, reporting a small number of cases, one resulting in aspiration pneumonia; patients should inform their healthcare providers.

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the mechanism of action of GLP-1 and dual GIP/GLP-1 receptor antagonist drugs contribute to the increased risk of aspiration during surgery?

Weight-loss drugs like Ozempic and Wegovy (containing semaglutide) and Mounjaro (containing tirzepatide) cause slow gastric emptying, increasing the risk of aspiration during surgery. This risk stems from the drugs' mechanism of action which delays the release of food and liquid from the stomach. The MHRA, along with European and U.S. medical authorities, acknowledges this risk, though more research is needed to establish a definitive causal link.

Showing 1 to 4 of 4 results